NextPoint Therapeutics, Inc.
Bijan Etemad-Gilbertson is an accomplished professional in the field of biotechnology with extensive experience in antibody technology and project management. Currently serving as Vice President of Antibody Technology at NextPoint Therapeutics, Inc. since May 2019, Bijan previously held the position of Director of Project Management at Surface Oncology Inc. from September 2017 to May 2019. Prior roles at Novartis Institutes for BioMedical Research included Associate Director of Biologics Initiatives and Lab Head between December 2006 and September 2017. Additional experience includes serving as Senior Scientist at AVEO Pharmaceuticals and Zycos, Inc., as well as a Postdoctoral position at Dana-Farber Cancer Institute. Bijan earned a Ph.D. in Genetics from Cornell University and a BS in Biology from Stony Brook University.
NextPoint Therapeutics, Inc.
NextPoint Therapeutics develops medications to expand the benefit of immunotherapies to cancer patients. The company offers immunotherapies for a validated checkpoint axis that is independent of PD-1/L1 and modulates both adaptive and innate immune systems to find and destroy cancer cells.